Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.

CRLNYSE / NASDAQHealthcareMid cap

$314.32-$13.61 (-4.2%)

Last close · Data as of Nov 20, 2026

Market cap
$8.9B
EV / EBITDA
27.5x
Revenue
$4.0B
Net margin
-3.6%
ROCE
0.1%

+93.9% over the last year

Charles River Laboratories International, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-0.4%
3M
+7.8%
6M
+101.4%
1Y
+93.9%
5Y
-17.3%

52-week range

Day change -$13.61 (-4.2%) from $328 to $314 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in CRL, bought on each weekday since 2021.

News & filings

What Charles River Laboratories International filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 144 million US dollars in fiscal 2025.

Strengths (1)

  • The price is 36.1% above its 200-day average, and the 50-day average is above the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.

Read moreShow less

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Sector
Healthcare
Shares outstanding
49.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$8.9B
P/B
2.8x
EV / EBITDA
27.5x
EV / Sales
2.8x
P/S
2.2x
52-week high
$376.10
52-week low
$149.93

Profitability

Operating margin
10.0%
Net margin
-3.6%
EBITDA margin
10.2%
ROE
-4.6%
ROCE
0.1%
ROA
-2.0%
Asset turnover
0.56

Growth

Revenue
$4.0B
Revenue growth, 1Y
-0.9%
Revenue CAGR, 3Y
0.3%
Net profit growth, 1Y
-1501.7%
Free cash flow
$518.5M

Solvency

Current ratio
1.29
Debt / Equity
0.81
Debt / Assets
0.36
CFO / Net profit
-5.11
Cash / Market cap
2.4%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$4.0B
Cost of revenue$2.7B
Gross profit$1.3B
Operating expenses$922.1M
Selling, general and administrative$743.1M
Operating income$401.1M
Interest and other-$500.6M
Pretax income-$99.5M
Tax and other$44.8M
Net income-$144.3M

Revenue and net profit

Revenue fell 0.9% in FY2025; net profit is the dashed line.

Charles River Laboratories International, Inc. revenue and net profit by fiscal year
Charles River Laboratories International, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$4.0B$486.2M
FY2023$4.1B$474.6M
FY2024$4.0B$10.3M
FY2025$4.0B-$144.3M

Cash flows

FY2025: $737.6M from operations, $518.5M free after investment (dashed).

Charles River Laboratories International, Inc. operating and free cash flow by fiscal year
Charles River Laboratories International, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$619.6M$294.9M
FY2023$683.9M$365.4M
FY2024$734.6M$501.6M
FY2025$737.6M$518.5M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$4.0B-0.9%1Y
EBITDA
$410.8M-29.3%1Y
Net profit
-$144.3M-1,501.7%1Y
Cash from operations
$737.6M+0.4%1Y
Free cash flow
$518.5M+3.4%1Y
Revenue CAGR, 3Y
0.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$4.0B$410.8M-$144.3M$518.5M-4.6%-0.9%-1501.7%

Monthly returns

Month-by-month returns of CRL across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$7.1B
Liabilities$3.9B
Equity$3.2B
Paid-in capital$1.9B
Retained earnings$1.4B
Treasury stock$0.00
Minority interest$46.6M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; CRL highlighted.

P/E against peers

CRL has no positive P/E; the peer median is 25.9x.

Not shown (no positive earnings and no EV / Sales): Charles River Laboratories International, Inc., Baxter International Inc., Glaukos Corporation.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Charles River Laboratories International, Inc.CRLthis company$8.9B—2.8x-4.6%27.5x
Molina Healthcare, Inc.MOH$10.0B21.3x2.5x11.6%—
Baxter International Inc.BAX$10.0B-10.4x1.6x-15.6%23.2x
Krystal Biotech, Inc.KRYS$9.1B44.3x7.4x16.8%51.2x
Henry Schein, Inc.HSIC$8.7B21.8x2.7x12.3%12.4x
Bio-Techne CorporationTECH$8.3B113.5x4.3x3.8%39.7x
Corcept Therapeutics IncorporatedCORT$8.0B80.7x12.4x15.4%66.1x
Alkermes plcALKS$7.2B29.9x4.0x13.3%20.9x
Glaukos CorporationGKOS$7.1B-38.1x10.9x-28.6%-49.0x
Peer median—25.9x4.2x11.9%23.2x

Year-to-date ROI

CRL since 1 January, against earlier years.

Historical volatility

CRL's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Charles River Laboratories International, Inc. operating margin by fiscal year
Charles River Laboratories International, Inc. operating margin by fiscal year
DateOperating margin
FY202216.4%
FY202314.9%
FY202410.9%
FY202510.0%
LineFY2025
Cost of revenueCost Of Revenue$2.7B
Gross profitGross Profit$1.3B
Operating expensesOperating Expense$922.1M
Selling, general and administrativeSelling General And Administration$743.1M
Depreciation and amortisationDepreciation And Amortization In Income Statement$179.1M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$179.1M
Amortization$179.1M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$179.1M
Total expensesTotal Expenses$3.6B
Pretax incomePretax Income-$99.5M

Learn while you research

Academy chapters picked for Charles River Laboratories International, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →